

Special Issue

Early-Stage and Operable Non-Small Cell Lung Cancer Treatment: Current Practice and Future Perspectives

Message from the Guest Editors

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the U.S. and globally. Over the last decade, however, incidence-based mortality rates have declined at accelerated rates, not only due to efforts in screening for detection of early-stage disease, but also due to remarkable advances in the treatment of metastatic NSCLC. These include the approval of checkpoint inhibitors and a variety of targeted therapies which require comprehensive biomarker testing. Over the last 5 years, a multitude of clinical trials investigating the role of such therapies for the improvement of long-term survival of operable patients has come to fruition. With the approval of targeted therapy and checkpoint inhibitors, a fast-paced change in the standard of care has demanded an integrated and effective multidisciplinary care of patients with operable NSCLC. This Special Issue will include narrative reviews on the current treatment, as well as future perspectives for the management of early-stage and operable patients with NSCLC, encompassing biomarker testing, advances in systemic therapy and surgical treatment, and their early rehabilitation.

Guest Editors

Dr. Francisco Aécio Almeida

Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA

Dr. Debora S. Bruno

Division of Hematology and Oncology, Case Western Reserve University Hospitals/Seidman Cancer Center, Cleveland, OH 44106, USA

Deadline for manuscript submissions

closed (20 May 2025)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/197437

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

jcm



About the Journal

Message from the Editorial Board

Journal of Clinical Medicine (ISSN 2077-0383) is an international, peer-reviewed, open access journal dedicated to advancing clinical and preclinical research. Our Editorial Board and staff are committed to delivering cutting-edge, timely, peer-reviewed articles spanning the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and impactful research articles, as well as reviews that are clinically significant and relevant to the full spectrum of medical disciplines. All full texts are archived in PubMed Central and indexed in SCIE (Web of Science), Scopus, PubMed, and other major databases. We invite you to submit your manuscript for publication, as well as join our community as a reviewer or reader online.

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).